WO1992010999A1 - Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes - Google Patents
Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes Download PDFInfo
- Publication number
- WO1992010999A1 WO1992010999A1 PCT/US1991/009201 US9109201W WO9210999A1 WO 1992010999 A1 WO1992010999 A1 WO 1992010999A1 US 9109201 W US9109201 W US 9109201W WO 9210999 A1 WO9210999 A1 WO 9210999A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bleeding
- powder
- surgery
- photograph
- blood
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
Definitions
- the substance powder 001 that can stop (stanch) bleeding in surgical, postsurgical, medical and dental uses or any bleeding due to any causes by topical administration or the substance powder 001 that has very potent hemostatic action can be administered topically to stop bleeding during surgery, after surgery, medicine by ingestion, dental surgery, extraction of teeth, and any injury or due to any causes for any normal and pathological persons.
- Tattersal and Seville 1950 reported purpura in 60 out of 809 elderly patients admitted to hospital; the bruises were most commonly seen on the anterior aspects of their arms and forearms. and on the backs of their hands, noth patients. and the controls were ascorbate deficient, as judged by ascorbic acid loading tests; skin biopsies from those with purpura showed degeneration of the collagen fibres of the dermis.
- THIS invention pertains to the field of disorder of hemostasis, which is further classified into evaluation of hemostatic function, platelet disorders, coagulation factor disorders and thromboembolic disorders.
- the blood coagulation mechanism of ascorbi c acid which was administered topically does not fall into either
- the present methods available to stop bleeding in surgery are cautery, epinephrine injection, pressure and some fiber foam.
- the cautery can cause tissue necrosis in
- the epinephrine, pressure and fiber foam can not work for bleeding tendency patients, and fiber foam can cause tissue hemotoma, nor can they work for diffuse capillary bleeding and oozing, while ascorbic acid does not cause any tissue necrosis and works particularly w el l for diffuse capillary bleeding and any traditionally uncontrollable bleeding tendency patients such as for patients with liver diseases, hemophilia and rectal anal cancer and for postoperation bleeding tendency of the kinds of aforementioned patients.
- the ascorbic acid can facilitate wound healing also ( Oral Surg 1982 Mar: 53(3): 231-6 ) by increasing type 1 procollagen mRNA in the regulation of col l agen synthesis ( Atherosclerosis 1982 Jan: 41(1): 15-9 ) (d) Explanation of Invention / Summary.
- Substance powder 001 represents ascorbic acid powder that is obtained by grinding the vitamin C tablets into powder. This powder has a very potent hemostatic action to stop bleeding when spraying it topically on the bleeding a rea for any
- hemophilia blood needs 0.1568 g of ascorbic acid powder.
- Sufficient substance powder 001 is particularly useful to help stop bleeding in the case of diffuse capillary oozing and mistakenly cut off artery or arteries that cannot be found during massive bleeding bleeding so as to save the patients' lives.
- the present methods available to stop bleeding in surgery as previously mentioned are cautery, epinephrine injection, pressure and some fiber foam.
- the cautery can cause tissue necrosis in some cases.
- the epinephrine, pressure and fiber foam can not cannot work for bleeding tendency and diffuse capi l l ary oozing patients, while ascorbic acid powder does not cause any tissue necrosis and particularly works well for diffuse capillary bleeding and oozing and any traditionally uncontrollable bleeding tendency patients such as for patients with liver diseases, hemophilia and colon rectal or other cancer bleeding conditions and for postoperation bleeding tendency of the kinds of aformentioned patients.
- the ascorbic acid also facilitate wound healing ( Oral Surg.
- the substance powder 001 is made by grinding the pure vitamin C tablets into powder.
- the amount of vitamin C powder needed to spray is proportional to the amount of blood coming out of the vessels. In test tube conditions, it requires 0.1568 g of this vitamin C powder to coagulate 1 ml of human blood. This is the same for normal, liver diseases, cancer, and hemophilia patients. The black coagulation takes place in 6 minutes by shaking the test tube. The description of this situation is made in the evidence of animal ( rats ) experiments and clinical evidence as follows:
- Sufficient substance powder 001 can stop massive bleeding of femoral artery within one second when femoral artery is cut off.
- Photograph # 1 massive bleeding when the femoral artery is cut off
- Photogrph # 2 bleeding stops within one second when sufficient powder of interest was poured topically into
- the amount of the powder needed is proportional to the amount of blood coming out of the vessel.
- Photograph # 3 In the case of capillary bleeding
- This powder also help stop massive bleeding in surgery, no matter what kind of diseases the patients suffered from.
- the operation of stopping bleeding consists of combining the powder with press with gauze.
- those that look black in color indicate the black blood coagulation ( Photograph # 14), while those that are white in color are those the powder does not get mixed up with the blood ( Photograph # 15).
- Photograph # 16 At the end of the operation, most of black blood coagulation was wiped out with 4x4 gauze, and rinsed with Ringer's solution ( Photograph # 16 ). It took totally 5 minutes to stop the bleeding completely. The patient's conditions are especially well, better than without using this powder.
- Photograph # 17 When the skin graft is removed from the hand,massive bleeding occurs ( Photograph # 17) . On applying sufficient powder to the bleeding area topically, it appears black coagulation within one second. Bleeding stops nt the same time ac the black coagulation forms. Those that appears white indicate the powder not yet mixed up with the blood. ( Photograph 4 18); those that appears more black area indicate the more powder mixed up with the blood (Photograph # 19), Suture going on ( Photograph # 20 ) Case 4. Age 70, female, paraanal abscess excision, bleeding when it is opened up ( Photograph # 21 ). When spraying the powder to the bleeding area, it stop bleeding by forming black blood coagulation immediately. Those that appears white are the powder that are not mixed up with the blood. ( Photograph # 212), Suture going on ( Photograph # 23 ).
- Photograph # 24 On spraying the powder topically to the bleeding area, the black color is formed immediately because of the blood coagulation ( Photograph # 25 ) .
- the white color is the powder instantly not mixed up with the blood yet. ( Photograph # 25 ), lastly, insert the long gauze into the anus. ( Photograph # 27 )
- Photograph # 29 Wipe out the black coagulation in 10 seconds, stop bleeding still persisted ( Photograph # 30 )
- blood requires 0.1568 g of powder to form black blood coagulation by shaking the tube with hand or stirer machine.
- Nan Tze District, Kaohsiung City lastly, Stops bleeding in tonsillectomy rat within one second by topical use of this (f). Claims of Utilities of ascorbic acid powder.
- this powder topically in to her bleeding nostril.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dental Preparations (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92901379A EP0644754A4 (en) | 1990-12-06 | 1991-12-05 | Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes. |
AU91034/91A AU662505B2 (en) | 1990-12-06 | 1991-12-05 | Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes |
NO1993930858A NO930858D0 (en) | 1990-12-06 | 1993-03-09 | SUBSTANCE THAT CAN STOP BLEEDING, eg. BY SURGICAL AND DENTAL INTERVENTIONS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62409490A | 1990-12-06 | 1990-12-06 | |
US624,094 | 1990-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992010999A1 true WO1992010999A1 (en) | 1992-07-09 |
Family
ID=24500629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/009201 WO1992010999A1 (en) | 1990-12-06 | 1991-12-05 | Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0644754A4 (en) |
AU (1) | AU662505B2 (en) |
CA (1) | CA2095439C (en) |
NO (1) | NO930858D0 (en) |
WO (1) | WO1992010999A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3755592A (en) * | 1971-02-19 | 1973-08-28 | G Ahrens | Method of preparing high concentration calcium ascorbate reaction products and products produced by same |
US4959362A (en) * | 1983-12-19 | 1990-09-25 | Takeda Chemical Industries, Inc. | Pharmaceutical compositions containing certain ascorbic acid derivatives useful in the prophylaxis and treatment of disorders of the circulatory system |
US5021452A (en) * | 1989-01-09 | 1991-06-04 | The Board Of Regents Of The University Of Washington | Process for enhancing wound healing |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2336925A1 (en) * | 1975-12-30 | 1977-07-29 | Mouney Guy | Dentifrice contg. haemostatic agent, esp. ascorbic acid or salt - has curative action on lesions of gingival epithelium etc. |
JPS6029361B2 (en) * | 1977-03-04 | 1985-07-10 | 白井松新薬株式会社 | Pharmaceutical composition with enhanced hemostatic effect |
NO161779C (en) * | 1986-04-22 | 1989-10-04 | Olav Johan Braenden | PROCEDURE FOR PREPARING AN ANTI-COOLING PREPARATION. |
US5140043A (en) * | 1989-04-17 | 1992-08-18 | Duke University | Stable ascorbic acid compositions |
-
1991
- 1991-12-05 WO PCT/US1991/009201 patent/WO1992010999A1/en not_active Application Discontinuation
- 1991-12-05 AU AU91034/91A patent/AU662505B2/en not_active Ceased
- 1991-12-05 EP EP92901379A patent/EP0644754A4/en not_active Withdrawn
- 1991-12-05 CA CA 2095439 patent/CA2095439C/en not_active Expired - Fee Related
-
1993
- 1993-03-09 NO NO1993930858A patent/NO930858D0/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3755592A (en) * | 1971-02-19 | 1973-08-28 | G Ahrens | Method of preparing high concentration calcium ascorbate reaction products and products produced by same |
US4959362A (en) * | 1983-12-19 | 1990-09-25 | Takeda Chemical Industries, Inc. | Pharmaceutical compositions containing certain ascorbic acid derivatives useful in the prophylaxis and treatment of disorders of the circulatory system |
US5021452A (en) * | 1989-01-09 | 1991-06-04 | The Board Of Regents Of The University Of Washington | Process for enhancing wound healing |
Non-Patent Citations (1)
Title |
---|
See also references of EP0644754A4 * |
Also Published As
Publication number | Publication date |
---|---|
AU9103491A (en) | 1992-07-22 |
NO930858D0 (en) | 1993-03-09 |
AU662505B2 (en) | 1995-09-07 |
EP0644754A1 (en) | 1995-03-29 |
EP0644754A4 (en) | 1995-12-27 |
CA2095439A1 (en) | 1992-06-07 |
CA2095439C (en) | 1998-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS6069028A (en) | Drug composition containing insulin | |
Muir | Text-book of Pathology | |
Maxwell et al. | Vascular complications of drug abuse | |
Redding | Thrombocythemia as a cause of erythermalgia | |
JPH04149126A (en) | Pharmaceutical composition for transmucous administration | |
FR2491475A1 (en) | PROCESS FOR THE PREPARATION OF CHONDROITI SULFATE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | |
RU2376993C2 (en) | Application of timosaponin b-ii in making drug or product for stroke prevention and treatment | |
AU662505B2 (en) | Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes | |
Collens et al. | The use of intermittent venous compression in the treatment of peripheral vascular disease: A preliminary report | |
CN104784193B (en) | Pharmaceutical application of protopanaxadiol type notoginsenoside | |
Burch et al. | Lower nephron syndrome | |
Diamond et al. | Kwashiorkor in a North American white male | |
US6783774B1 (en) | Substance that stop any kind of bleeding within one second for medical, surgical, postsurgical and dental uses | |
Vaughan et al. | Skin necrosis of genitalia and warfarin therapy | |
JP2009191015A (en) | Wound healing promoter | |
CN106806377A (en) | The pharmaceutical applications of notoginsenoside Fc | |
Chandler et al. | Benign duodeno-colonic fistula | |
Clements | Manifestations of nutritional deficiency in infants | |
CN106806378B (en) | The pharmaceutical applications of notoginsenoside Fc | |
Krishna | Study of Surgincal Complicatons in Diabetic Patients Among The Rural Population | |
Pederson | Physiology and treatment of severe burns: with special reference to burn shock | |
RU2228194C2 (en) | Means for preventing from hemorrhagic blood-coagulating and edematous necrotic activity of snake venom | |
Smith | Laparoscopic cholecystectomy. | |
RU2487664C1 (en) | Gizatullin's method of determining optimal volume of infusion therapy for injured in frostbites in state of narcotic intoxication after application of dezomorphin | |
Holman et al. | Hypoproteinemia as protection against mercuric chloride injury in dogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR NO |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2095439 Country of ref document: CA |
|
122 | Ep: pct application non-entry in european phase | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1992901379 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992901379 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992901379 Country of ref document: EP |